Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib/dexamethasone versus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
2016-004742-28Phase 2Completed
- Sponsor
- Takeda
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in multiple myeloma (MM) comparing Ixazomib + dexamethasone with Imnovid + dexamethasone (2 arms). Started Aug 2017; status: completed.
02
Drugs
ixazomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-004742-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004742-28.